| Primary |
| Graft Versus Host Disease |
34.0% |
| Immunosuppression |
10.0% |
| Eczema |
7.0% |
| Product Used For Unknown Indication |
6.0% |
| Chronic Graft Versus Host Disease |
5.0% |
| Enterocolitis |
5.0% |
| Chronic Obstructive Pulmonary Disease |
4.0% |
| Nasopharyngitis |
4.0% |
| Adrenal Insufficiency |
3.0% |
| Conjunctivitis Allergic |
3.0% |
| Vulvovaginal Candidiasis |
3.0% |
| Antifungal Prophylaxis |
2.0% |
| Drug Use For Unknown Indication |
2.0% |
| Dyspepsia |
2.0% |
| Infection Prophylaxis |
2.0% |
| Psoriasis |
2.0% |
| Rash |
2.0% |
| Ulcer |
2.0% |
| Antiviral Prophylaxis |
1.0% |
| Arthropod Bite |
1.0% |
|
| Glaucoma |
12.5% |
| Chorioretinopathy |
8.3% |
| Diabetes Mellitus |
8.3% |
| Diabetes Mellitus Inadequate Control |
8.3% |
| Psoriasis |
8.3% |
| Burning Sensation |
4.2% |
| Dizziness |
4.2% |
| Haemorrhage |
4.2% |
| Haemorrhage Subcutaneous |
4.2% |
| Hypoglycaemia |
4.2% |
| Hypokalaemia |
4.2% |
| Immobile |
4.2% |
| Opportunistic Infection |
4.2% |
| Pneumonia |
4.2% |
| Rash |
4.2% |
| Secondary Adrenocortical Insufficiency |
4.2% |
| Skin Depigmentation |
4.2% |
| Thinking Abnormal |
4.2% |
|
| Secondary |
| Graft Versus Host Disease |
32.0% |
| Psoriasis |
14.4% |
| Immunosuppression |
9.4% |
| Chronic Graft Versus Host Disease |
4.7% |
| Enterocolitis |
4.7% |
| Pyoderma Gangrenosum |
4.7% |
| Nasopharyngitis |
3.8% |
| Pustular Psoriasis |
3.8% |
| Adrenal Insufficiency |
2.8% |
| Conjunctivitis Allergic |
2.8% |
| Ulcer |
2.5% |
| Antifungal Prophylaxis |
1.9% |
| Dyspepsia |
1.9% |
| Hypertension |
1.9% |
| Infection Prophylaxis |
1.9% |
| Osteoporosis |
1.9% |
| Rash |
1.9% |
| Dermatitis Atopic |
1.3% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Constipation |
0.9% |
|
| Secondary Adrenocortical Insufficiency |
21.1% |
| Hepatic Function Abnormal |
10.5% |
| Tension Headache |
10.5% |
| Acne |
5.3% |
| Adrenocortical Insufficiency Acute |
5.3% |
| Cataract |
5.3% |
| Drug Exposure During Pregnancy |
5.3% |
| Incorrect Drug Administration Duration |
5.3% |
| Mechanical Ventilation |
5.3% |
| Pneumonia |
5.3% |
| Skin Ulcer |
5.3% |
| Synovitis |
5.3% |
| Vomiting |
5.3% |
| Wound Dehiscence |
5.3% |
|
| Concomitant |
| Psoriasis |
25.0% |
| Chronic Hepatitis C |
13.1% |
| Product Used For Unknown Indication |
13.0% |
| Prophylaxis |
9.8% |
| Hypertension |
3.9% |
| Rash |
3.8% |
| Hepatitis C |
3.3% |
| Eczema |
3.0% |
| Insomnia |
2.8% |
| Dermatitis Atopic |
2.6% |
| Psoriatic Arthropathy |
2.6% |
| Pustular Psoriasis |
2.6% |
| Pruritus |
2.5% |
| Erythrodermic Psoriasis |
2.2% |
| Drug Use For Unknown Indication |
2.2% |
| Adverse Event |
1.8% |
| Rheumatoid Arthritis |
1.6% |
| Pain |
1.5% |
| Constipation |
1.4% |
| Diabetes Mellitus |
1.3% |
|
| Toxic Skin Eruption |
19.5% |
| Rash |
9.7% |
| White Blood Cell Count Decreased |
9.1% |
| Drug Eruption |
6.5% |
| Glucose Tolerance Impaired |
5.2% |
| Platelet Count Decreased |
4.5% |
| Pyrexia |
4.5% |
| Hepatic Function Abnormal |
3.9% |
| Pneumonia |
3.9% |
| Retinopathy |
3.9% |
| Trismus |
3.9% |
| Erythema Multiforme |
3.2% |
| Toxic Epidermal Necrolysis |
3.2% |
| White Blood Cell Count Increased |
3.2% |
| Breast Cancer |
2.6% |
| Cellulitis |
2.6% |
| Neutrophil Count Decreased |
2.6% |
| Oxygen Saturation Decreased |
2.6% |
| Partial Seizures |
2.6% |
| Pleural Effusion |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
76.9% |
| Asthma |
7.7% |
| Epicondylitis |
7.7% |
| Erythema |
7.7% |
|
| Drug Interaction |
33.3% |
| Dyspnoea |
33.3% |
| Pulmonary Embolism |
33.3% |
|
